Status:
COMPLETED
Open-Label Trial of Sulforaphane in Premutation Carriers With FXTAS
Lead Sponsor:
University of California, Davis
Conditions:
Fragile X Associated Tremor/Ataxia Syndrome (Fxtas) (Diagnosis)
Eligibility:
All Genders
50-85 years
Phase:
NA
Brief Summary
FXTAS is a rare genetic progressive neurodegenerative disorder, linked to a trinucleotide repeat expansion in the FMR1 gene. FXTAS is characterized by tremor and ataxia in addition to atrophy and whit...
Eligibility Criteria
Inclusion
- Diagnosis of FXTAS
- Presence of a FMR1 premutation (55 to 200 CGG repeats)
Exclusion
- Individuals with severe renal failure (GFR is \<60 ml/min/1.73 m\^2)
- Significant and current reported substance abuse
- Individuals with substance use disorder (meets 6 or more symptoms of substance use disorder criteria)
- Any subject on hospice or on home oxygen
- Individuals who are pregnant
Key Trial Info
Start Date :
June 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2023
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05233579
Start Date
June 25 2021
End Date
January 1 2023
Last Update
July 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UC Davis MIND Institute
Sacramento, California, United States, 95817